hormoneNot FDA-approvedPrescription only (US)Not FDA-approved; the new drug application was not grantedAvailable only through compounding pharmaciesProhibited in sport (WADA S4)
EnclomipheneBenefits, Dosage & Interactions
Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Moderate — Covered by a systematic review, without regulatory approval.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
Covered by a systematic review, without regulatory approval.
Plasma half-life
~10 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Enclomiphene in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Enclomiphene entry is written from. Each number matches an inline marker above.
- [1]Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trialsHohl A, et al. · Archives of Endocrinology and Metabolism · 2025 · Peer-reviewed · PMID 41066380
- [2]Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysisTienforti D, Castellini C, Di Giulio F, et al. · Andrology · 2023 · Peer-reviewed · PMID 36604313
How to track Enclomiphene doses
Enclomiphene is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Enclomiphene is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Enclomiphene comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 10 h, effects and timing shifts show up over days rather than instantly. Review Enclomiphene alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Enclomiphene dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Enclomiphene studied for?
What is Enclomiphene?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women. While clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene, enclomiphene is thought to be the primary therapeutically active component responsible for stimulating gonadotropin release. In men, secondary hypogonadism is characterized by low testosterone levels due to impaired testicular function resulting from abnormal pituitary or hypothalamic signaling. Enclomiphene aims to address this by modulating estrogen receptors, ultimately leading to increased endogenous testosterone production.
Unlike traditional testosterone replacement therapy (TRT), which introduces exogenous testosterone and can suppress natural production, enclomiphene works by stimulating the body's own hormone-producing mechanisms. This distinction is significant for men who wish to maintain their own testicular function and fertility. Enclomiphene is typically administered orally.
What does the research say about Enclomiphene?
Tap a section to expand.
Enclomiphene acts as a selective estrogen receptor modulator (SERM). Its primary mechanism of action in men involves antagonism of estrogen receptors in the hypothalamus and pituitary gland. The hypothalamus detects circulating estrogen levels and, in response to lower perceived estrogen, releases gonadotropin-releasing hormone (GnRH). GnRH then stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH, in turn, stimulates the Leydig cells in the testes to produce testosterone, while FSH supports spermatogenesis. By blocking estrogen's negative feedback at these critical points, enclomiphene effectively "tricks" the hypothalamus and pituitary into believing that estrogen levels are low, thereby increasing the secretion of LH and FSH, which subsequently leads to an increase in endogenous testosterone production. This process helps to restore a more normal hormonal balance in men with secondary hypogonadism, promoting natural testosterone synthesis without directly introducing exogenous hormones. (Source: PubChem, DrugBank)
Source for this section: Sources for How does Enclomiphene work?: Jumps to this entry in the sources and references list at the end of the page.
The primary potential benefit of enclomiphene for men with secondary hypogonadism is an increase in endogenous testosterone levels. This increase may lead to improvements in various symptoms associated with low testosterone, such as:
* **Improved Libido:** Low testosterone is often linked to decreased sex drive, and restoring testosterone to healthy levels can alleviate this.
* **Enhanced Energy Levels:** Many men with hypogonadism experience fatigue, and increased testosterone may help boost energy and reduce tiredness.
* **Improved Mood:** Low testosterone has been associated with mood disturbances, including irritability and mild depression. Normalizing testosterone levels may help stabilize mood.
* **Increased Muscle Mass and Strength:** Testosterone plays a crucial role in muscle protein synthesis. Higher testosterone levels can support muscle growth and strength, particularly when combined with resistance training. This aligns with enclomiphene's classification under the 'muscle' goal tag.
* **Improved Bone Density:** Testosterone contributes to maintaining bone mineral density. Increasing testosterone may help reduce the risk of osteoporosis.
* **Maintenance of Testicular Function and Fertility:** Unlike external testosterone replacement therapy, enclomiphene aims to stimulate the testes directly, which can help preserve natural testicular function and sperm production. This is a significant advantage for men who are concerned about fertility. (Source: DrugBank, investigational studies)
It is important to note that while these benefits are observed in studies, individual responses can vary. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Clinical trials and research studies have explored the efficacy and safety of enclomiphene in men with secondary hypogonadism. A review of studies indicates that enclomiphene reliably increases serum total testosterone and LH levels in men with low testosterone. For example, a controlled study, as referenced by an FDA label for a related compound, demonstrated that enclomiphene significantly increased total testosterone levels above the lower limit of the normal range. These increases were often accompanied by improvements in symptoms associated with hypogonadism. Furthermore, some studies have shown that enclomiphene can increase sperm concentration and motility, suggesting a potential role in preserving fertility in hypogonadal men, a key differentiator from exogenous testosterone treatments. More specific details regarding these studies, including their methodologies and patient populations, can be found in peer-reviewed scientific literature and regulatory submissions. (Source: FDA label (related compounds), PubChem, scientific literature).
While generally considered to be well-tolerated, enclomiphene may cause some side effects, which can vary in severity and frequency among individuals. Common side effects reported in clinical trials include:
* **Headache:** A frequently reported side effect.
* **Nausea:** Some users may experience stomach upset.
* **Fatigue:** Paradoxically, while aimed at improving energy, some individuals might experience fatigue.
* **Dizziness:** Occasional reports of lightheadedness.
* **Hot Flashes:** Similar to effects seen with other SERMs, hot flashes can occur due to estrogen receptor modulation.
* **Acne:** Hormonal changes can sometimes trigger or worsen acne.
* **Visual Disturbances:** Although less common, some individuals have reported blurred vision or other visual symptoms. This warrants immediate medical attention if experienced.
* **Mood Changes:** Shifts in mood, including irritability or anxiety, have been noted in some cases.
Less common but more serious side effects may include changes in liver enzymes, though these are typically transient. It is crucial to report any persistent or concerning side effects to a healthcare professional.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering enclomiphene should be aware of several warnings and precautions. Enclomiphene is generally contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should be used with caution in men with existing liver impairment, as liver function tests may need to be monitored. Patients with a history of visual disturbances should be closely monitored, and any new visual symptoms should prompt immediate discontinuation and medical evaluation. Hormone-sensitive conditions, such as prostate cancer, should be ruled out before initiating enclomiphene therapy, as modulating testosterone levels could potentially affect such conditions. Regular monitoring of testosterone, LH, and FSH levels, as well as general health markers, is recommended during treatment to assess efficacy and safety. Given its impact on hormonal axes, enclomiphene is a controlled compound, meaning its use must be under the direct supervision and prescription of a licensed clinician.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Enclomiphene is contraindicated in several circumstances to ensure patient safety. These include:
* **Known Hypersensitivity:** Individuals with a documented allergic reaction to enclomiphene or any of its excipients should not use this compound.
* **Pregnancy and Lactation:** While primarily for men, it is contraindicated in women who are or may become pregnant, or who are breastfeeding, due to potential adverse effects on fetal development or infants. This is consistent with its estrogen receptor modulator activity.
* **Unexplained Vaginal Bleeding:** In women, and as a component of clomiphene citrate, it is contraindicated in cases of unexplained vaginal bleeding.
* **Liver Disease or Impairment:** Individuals with active liver disease or significant liver dysfunction should avoid enclomiphene due to potential hepatotoxicity.
* **Adrenal or Thyroid Dysfunction:** Enclomiphene is contraindicated in individuals with uncontrolled adrenal or thyroid gland dysfunction, as it can interfere with other hormonal pathways.
* **Hormone-Dependent Tumors:** Any known or suspected hormone-dependent tumors, such as prostate cancer, are a contraindication due to the direct or indirect influence on hormone levels within the body.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to its mechanism of action and effects on hormone levels, enclomiphene should be used with caution, if at all, when combined with certain other compounds. Specific interactions may include:
* **Other Hormone-Modulating Therapies:** Concomitant use with other drugs that significantly alter testosterone, estrogen, or gonadotropin levels (e.g., exogenous testosterone replacement, aromatase inhibitors, other SERMs) could lead to unpredictable hormonal imbalances or exacerbated side effects. Such combinations would require very careful monitoring and clinician oversight.
* **Drugs Metabolized by the Liver:** Although enclomiphene's primary metabolism pathways are not explicitly detailed as major drug interaction concerns, caution is always advised when combining with other compounds that place a significant burden on hepatic metabolism, particularly in individuals with pre-existing liver conditions.
* **Drugs Affecting Vision:** Given the potential for visual disturbances with enclomiphene, co-administration with other medications known to cause ocular side effects should be approached with caution and under medical guidance.
Always inform your healthcare provider about all medications, supplements, and herbal products you are currently taking to avoid potential adverse interactions.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Enclomiphene is typically administered orally. The timing and frequency of administration are user-directed and must be set by a licensed clinician based on individual patient needs, hormonal profiles, and treatment goals. Dosing regimens can vary, and continuous daily dosing or cyclical regimens may be used. It is essential to follow the specific instructions provided by your clinician and to take enclomiphene consistently at the prescribed times to maintain stable drug levels and optimize therapeutic effects. Enclomiphene can generally be taken with or without food, but specific instructions from your clinician should always be followed.
Source for this section: Sources for When should you take Enclomiphene?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Enclomiphene?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Enclomiphene
Enclomiphene is a hormone. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Enclomiphene is commonly discussed in the context of supporting testosterone, brain, bone-joint, and muscle. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Enclomiphene, it is typically taken null and its approximate half-life is 10 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Enclomiphene carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Enclomiphene is classified as a controlled substance in some jurisdictions, so legal status and prescribing rules apply. Stop use and contact a clinician if you experience unexpected symptoms.
As a hormone, Enclomiphene can overlap with other supplements, prescription medicines, hormones and peptides. With a reported plasma half-life near 10 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Enclomiphene with no sign-up.
Whether Enclomiphene fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Enclomiphene. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 10 hours, once-daily dosing is the usual pattern for Enclomiphene. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 10 hours, a single missed dose of Enclomiphene usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Enclomiphene the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Enclomiphene?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials(opens PubMed in a new tab)Arch Endocrinol Metab · 2025 · PMID 41066380 · https://pubmed.ncbi.nlm.nih.gov/41066380/
- 2.Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.(opens PubMed in a new tab)BJU international · 2013 · PMID 23875626 · https://pubmed.ncbi.nlm.nih.gov/23875626/
- 3.Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men(opens PubMed in a new tab)IDrugs · 2009 · PMID 19204885 · https://pubmed.ncbi.nlm.nih.gov/19204885/
- 4.Enclomiphene citrate for the treatment of secondary male hypogonadism(opens PubMed in a new tab)Expert Opin Pharmacother · 2016 · PMID 27337642 · https://pubmed.ncbi.nlm.nih.gov/27337642/
- 5.Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone(opens PubMed in a new tab)Fertil Steril · 2014 · PMID 25044085 · https://pubmed.ncbi.nlm.nih.gov/25044085/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 1548953(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/1548953
Verify at
Publisher search links for Enclomiphene. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Enclomiphene?
Plain-text summary, safe to quote verbatim:
Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women.
Source: DoseRoutine — https://doseroutine.com/library/enclomiphene
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Enclomiphene — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/enclomiphene
What compounds are similar to Enclomiphene?
Others in the hormone category or studied for the same goals.
Which goals is Enclomiphene used for?
Other compounds studied for the same benefits as Enclomiphene.
Continue exploring
See every compound DoseRoutine catalogs for these goals.